Fresenius: sales and earnings growth in the first-quarter.

(CercleFinance.com) - German healthcare group Fresenius SE has announced that its sales and earnings have edged up in the first quarter, particularly bolstered by strategic acquisitions.


Quarterly adjusted net income rose increased by 28% to 457 million euros, while group sales rose 19% to 8.4 billion euros. Organic growth was 7%.

While Fresenius confirmed its sales outlook for 2017, the company raised its earnings guidance published in February 2017.

On a like-for-like basis, group net income, before effects of the recently announced acquisitions at Fresenius Kabi, is now expected to increase by 19% to 21% at constant currencies, compared to 17% to 20% previously.

Fresenius Medical Care, the world's largest provider of products for chronic kidney failure, which is controlled by Fresenius, said in a separate statement that Q1 net income increased by 45% to 308 million euros, on sales that were up 16% at 4.5 billion euros.

Listed on the DAX index, Fresenius SE shares were up 2.7% at 77.7 euros in early trading this morning, while Fresenius Medical Care shares were down 0.3% at 83.5 euros.

Copyright (c) 2017 CercleFinance.com. All rights reserved.